Stanley Druckenmiller
JUNO

Stanley Druckenmiller’s Juno Therapeutics, Inc. JUNO Stock Holding History

Stanley Druckenmiller’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-493,000
Closed -$14.8M – 59
2016
Q3 		$14.8M Buy
+493,000
New +$15.3M 1.31% 33
2015
Q1 		– Sell
-70,000
Closed -$3.65M – 48
2014
Q4 		$3.65M Buy
+70,000
New +$3.13M 0.36% 34

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Stanley Druckenmiller's JUNO Position: Q4 2016 in Review

Stanley Druckenmiller sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 493,000 shares — an estimated $14.8M sold.

Stanley Druckenmiller first reported a position in JUNO in Q4 2014 and held it in 2 quarters. The position peaked at $14.8M in Q3 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • Stanley Druckenmiller reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Stanley Druckenmiller sold 493,000 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $14.8M.
  • Stanley Druckenmiller first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
  • Stanley Druckenmiller's Juno Therapeutics, Inc. position peaked at $14.8M in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Duquesne Family Office's 13F filing for Q4 2016, filed 14 Feb 2017.